Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Diethyldithiocarbamate** is the anionic form of diethyldithiocarbamic acid and is most recognized as the primary metabolite of disulfiram, a drug used in the management of alcohol dependence. It acts as a **chelating agent**, capable of binding soft metal ions and increasing their elimination from tissues in both experimental animals and humans. Diethyldithiocarbamate is used to mobilize toxic metals, has been investigated as an **orphan drug for AIDS**, and studied as an adjunct in various cancer and liver disease research settings. Mechanistically, it is a known **inhibitor of cytochrome P450 2E1** and **nuclear factor kappa-B (NF-κB)**, possessing antioxidant properties and affecting other signaling pathways including those relevant to liver fibrosis. It also exhibits **superoxide dismutase inhibition** and can impact immune cell signaling and response[1][3][5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diethyldithiocarbamate.